Status:
RECRUITING
Comparison of the Analgesic Effect of 2 Shoulder Infiltrations
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Conditions:
Infiltration
Shoulder Osteoarthritis
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
For patients suffering of osteoarthritis, only analgesic treatments such as anti-inflammatory drugs and cortisone infiltrations provide significant but temporary relief of their pain. The objective is...
Detailed Description
Osteoarthritis is a degenerative joint disease. The progressive erosion of cartilage generates inflammation, pain, and progressive deterioration of joint mobility. Synthetic molecules similar to hyalu...
Eligibility Criteria
Inclusion
- A clinical examination that confirms the radiological diagnosis of moderate to severe primary shoulder osteoarthritis, stage II and above, according to the Samilson-Prieto classification.
- Patients aged between 20 and 90 years.
- A patient with bilateral shoulder osteoarthritis will choose the side of the infiltration, only one side can be chosen to participate in the study.
- The patient must have a clinical pain threshold of a minimum of 4/10 on the visual analogue scale.
- The patient must have the cognitive ability to read and fill out the questionnaires.
- The patient must be able to read and understand French or English
Exclusion
- Presence of a transfixing rotator cuff tear assessed on MRI.
- No previous shoulder reconstruction surgery.
- Pregnant woman.
- A patient who has received a cortisone infiltration within 6 months prior to the start of the study.
- A patient who has received a platelet-rich plasma or a hyaluronic acid infiltration within 12 months prior to the start of the study.
- Diagnosis of avascular necrosis.
- Disease affecting the studied joint (systemic inflammatory disease, history of septic arthritis, osteonecrosis, etc.)
- Suspicion or presence of active local infectious process.
- Presence or suspicion of neoplasia or local metastasis.
- Severe trauma to the shoulder ( ≤ 3 months)
- Significant cognitive impairment or insufficient language proficiency to adequately answer the questionnaires.
- Any other serious medical condition that does not allow participation in the study or may be a contraindication to cortisone injection.
Key Trial Info
Start Date :
November 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT05408065
Start Date
November 15 2022
End Date
December 1 2026
Last Update
February 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada, H2X 0C1